Abstract
In a span of less than a week, the US Food and Drug Administration approved two new therapies, each of which is a first-in-class treatment for its respective disease. The first to receive the nod was Provention Bio’s teplizumab, an antibody that can delay the onset of type 1 diabetes in patients 8 years and older. Days later came approval for CSL Behring’s Hemgenix, the first gene therapy for hemophilia B. The one-time treatment restores peoples’ ability to produce proteins that help with blood clot formation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
